Cancer Vaccine Acceleration Company

Cancer Vaccine Acceleration Company (CVAC) is a UK-based subsidiary of BioNTech, established in 2023 to spearhead the development and clinical testing of personalized mRNA cancer vaccines. Operating in close collaboration with the UK Department of Health and Social Care and NHS England, CVAC is the primary vehicle for the Cancer Vaccine Launch Pad initiative. The company focuses on BioNTech's individualized neoantigen specific immunotherapy (iNeST) platform, which tailors treatments to the unique genetic profile of a patient's tumor. CVAC facilitates large-scale clinical trials across the UK, aiming to provide innovative immunotherapies to thousands of patients. Its activities integrate advanced genomic sequencing with rapid manufacturing processes to deliver precision oncology solutions. By leveraging the UK's clinical research infrastructure, CVAC aims to accelerate the timeline from tumor biopsy to vaccine administration.